FDA Approves First Targeted Therapy to Treat Patients with Painful Complication of Sickle Cell Disease
Felicia Rodriguez
November 20, 2019
VIA: https://www.worldpharmanews.com/fda/5020-fda-approves-first-targeted-therapy-to-treat-patients-with-painful-complication-of-sickle-cell-disease Today, the U.S. Food and Drug Administration approved Adakveo (crizanlizumab-tmca), a treatment to reduce the frequency of vaso-occlusive crisis – a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells – for